Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target

Qianru Leng, Jie Ding, Meiyian Dai, Lei Liu, Qing Fang, Dao Wen Wang, Lujin Wu* and Yan Wang*

Division of Cardiology, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Non-communicable diseases (NCDs), represented by cardiovascular diseases and cancer, have been the leading cause of death globally. Improvements in mortality from cardiovascular (CV) diseases (decrease of 14%/100,000, United States) or cancers (increase 7.5%/100,000, United States) seem unsatisfactory during the past two decades, and so the search for innovative and accurate biomarkers of early diagnosis and prevention, and novel treatment strategies is a valuable clinical and economic endeavor. Both tumors and cardiovascular system are rich in angiological systems that maintain material exchange, signal transduction and distant regulation. This pattern determines that they are strongly influenced by circulating substances, such as glycolipid metabolism, inflammatory homeostasis and cyclic non-coding RNA and so forth. Platelets, a group of small anucleated cells, inherit many mature proteins, mRNAs, and non-coding RNAs from their parent megakaryocytes during gradual formation and manifest important roles in inflammation, angiogenesis, atherosclerosis, stroke, myocardial infarction, diabetes, cancer, and many other diseases apart from its classical function in hemostasis. MicroRNAs (miRNAs) are a class of non-coding RNAs containing ~22 nucleotides that participate in many key cellular processes by pairing with mRNAs at partially complementary binding sites for post-transcriptional regulation of gene expression. Platelets contain fully functional miRNA processors in their microvesicles and are able to transport their miRNAs to neighboring cells and regulate their gene expression. Therefore, the importance of platelet-derived miRNAs for the human health is of increasing interest. Here, we will elaborate systematically the roles of platelet-derived miRNAs in cardiovascular disease and cancer in the hope of providing clinicians with new ideas for early diagnosis and therapeutic strategies.

Keywords: platelet, MicroRNAs, cardiovascular diseases, cancer, platelet-derived microvesicle (PMV)
INTRODUCTION

The latest WHO report released in December 2020 shows that non-communicable diseases (NCDs), represented by cardiovascular and oncolgic diseases, have been the leading cause of global death over the past 20 years (1). Cardiovascular diseases (CVDs), principally ischemic heart disease, heart failure and stroke, account for one-third of the annual deaths and also are the major contributors to disability (2). However, the global incidence and mortality of CVDs have continued to rise uncontrollably, with an increase of 93 and 54%, respectively, for the last three decades (1, 3). The second cause of death is cancer, with 24.5 million incident cases worldwide and 9.6 million deaths in 2017 (4, 5). With the aging of social population, the deterioration of environment, the prevalence of obesity and the deterioration of lifestyle (smoking, alcohol, drugs nightlife, and physical inactivity), the incidence of cardiovascular and oncolgic diseases is bound to grow. Despite massive researches funding and government spending, the ultimate efficacy of both diseases is far from satisfactory, most likely because of limited access to timely diagnosis and standard treatment. In fact, 5-year survival rates for heart failure and lung cancer are less than 25 and 17%, respectively (6, 7).

Platelets are small anuclear cell fragments in the circulating blood. Although platelets could not transcribe the gene, the complete translational and post-transcriptional regulation machinery including miRNA, non-coding RNAs, ribosomes, and initiation/termination factors are inherited from megakaryocyte and stored in the cytoplasm and granules during thrombopoiesis (8, 9). Platelet activation dependent on specific receptors [such as glycoprotein Ib-IX-V (GPIb-IX-V), purinergic receptors (P2Y1 and P2Y12), and integrin αIIbβ3] on their surface is the key step for platelet function (10, 11). Once activated, platelets quickly secrete granules and intracellular active substances such as P-selectin, soluble CD40 ligand (sCD40L), platelet factor 4 (PF4) and interleukin-1 beta (IL-1β) via exocytosis pathway. These substances contribute to platelet adhesion, aggregation, platelet-leukocyte crosstalk, platelet-endothelial crosstalk and systemic inflammation states (12–14). These actions are important mechanisms by which platelets are involved in thrombosis, cardiac remodeling after myocardial infarction, atherosclerosis, diabetic microangiopathy, tumor growth, and metastasis (13, 15–18). Besides these proteins, platelets inherit a variety of nucleic acids including non-coding RNAs (miRNAs as well as lncRNAs) and messenger RNAs (mRNAs). In recent years, in-depth transcriptional analyses identified up to 532 different miRNAs and as many as 3000–6000 mRNAs in human platelets (19, 20).

As we known, miRNAs are highly conserved, small endogenous non-coding RNAs negatively regulating gene expression at the post-transcriptional level by complementary sequence recognition, and are involved in many pathophysiological processes, including cardiovascular diseases and cancer. An enormous amount of research has gradually described the strong biological effects of platelet-derived miRNAs. They not only regulate the synthesis of platelet protein but also are transferred to endothelial cells, smooth muscle cells (SMCs), macrophages, and tumor cells, where they bind to host cells’ mRNAs (21–23). However, a systematic review about the role and mechanism of platelet-derived miRNAs on two highly lethal diseases, cardiovascular disease and cancer, is lacking.

In this study, we explore the possibility of circulating platelet-derived miRNAs as early diagnosis and prognostic factors, and their roles in the occurrence and development of cardiovascular diseases and tumors, which may provide clinicians with new diagnostic and therapeutic targets for these diseases.

The Origin of Platelets MicroRNAs

MicroRNAs are a class of regulatory non-coding RNAs with a length of ~22 nucleotides expressed in multicellular organisms and synthesized by an elaborate system involving numerous protein-protein and protein-RNA interactions (24, 25). Briefly, miRNA-related genes are firstly transcribed into primary miRNAs (pri-miRNAs) by RNA polymerase II (Pol II), and subsequently pri-miRNAs are processed into shorter precursor miRNAs (pre-miRNAs) by a complex formed by the RNAase-III enzyme Drosha and its interaction partner DGCR8 in the nucleus. Next, pre-miRNAs are transported out of the nucleus by exportin-5. In the cytoplasm, RNase Dicer enzyme bound to the double-stranded RNA with protein TRBP cleaves pre-miRNAs into shorter double-stranded miRNAs. Finally, double-stranded miRNAs are replicated into argonaute 2 (Ago2) and form the miRNA-induced silencing complex (RISC). One strand of the double-stranded miRNA is retained in the RISC complex, and the other strand is expelled from the complex and rapidly degraded. The RISC complex containing the miRNA single strand can function in subsequent gene regulation processes (26).

Since platelets are anucleate, mature miRNAs in platelets were previously considered remnants of megakaryocytes. However, later studies confirmed that anucleate platelets possess complete elements (Dicer, Ago2, and TRBP2) which can machine precursor miRNA (pre-miRNA) into mature miRNA in their cytoplasm (27), but lack of nuclear microprocessor components Drosha and DGC8R. The function of platelet Dicer enzyme was confirmed since miRNA-sized RNA fragments were obtained when a radioactive Dicer substrate 32P-labeled pre-let-7a-3 was co-cultured with platelet extracts (27). Additionally, their research also confirmed that platelets harbor functional Ago2–miRNA complexes. The direct interaction between Ago2 with endogenous mature miR-223 was confirmed by northern blotting of platelets Ago2 immunoprecipitation and the inhibitory expression of target gene P2Y12 confirmed the regulatory function of the Ago2-miR-223 complex (27). These results suggested that platelets have the ability to produce mature miRNA by processing pre-miRNA templates.

However, evidence suggests that a large proportion of mature miRNAs contained in platelets are mainly inherited from megakaryocytes (28). Cultured megakaryocytes transcribes multiple miRNAs, which correlates well with the content of miRNAs found in platelets (28, 29). Platelets inherit RNA pool, including pre-miRNAs, from their parent megakaryocytes (30, 31). These RNAs become important sources of platelet miRNA as they may be processed into mature miRNA by functional Dicer as templates (22, 27). Besides, miRNAs can bidirectionally transfer between platelets and the surrounding environment (32).
RNA uptake from contacting cells or the circulating blood is also thought to be a contributor to miRNA diversity within platelets (30, 33). In general, platelets can not only inherit a large amount of miRNAs from megakaryocytes and take up part of miRNAs from surrounding environment, but also can process the inherited and ingested RNAs into miRNAs (Figure 1).

The Content of Platelets MicroRNAs
As early as in 2008, Bruchova et al. first detected abundant miR-26b in platelets in patients with polycythemia vera and essential thrombocythemia (34). This was the first study attracting our attention to platelet-derived miRNAs. Later, a large number of studies confirm that platelets contain a wide variety of miRNAs, although platelet-derived miRNAs are much less than those in nucleated blood cells (35, 36). With the development of microarray and sequencing technology, more miRNAs have been identified in platelets. Landry et al. identified 219 miRNAs in purified leukocyte-depleted platelet by locked nucleic acid (LNA) microarray profiling in 2009. Among them, miR-223, let-7c, and miR-19a were the three most abundant miRNAs according to their results (27). Subsequent studies on the most common miRNAs in platelets were inconsistent (Table 1). In many studies, miR-223-3p was described as the most abundant platelet-derived miRNA (37ñ39). Later, the first next-generation sequencing (NGS) data on platelet miRNAs was published, identifying 532 miRNAs present in platelets, with the let-7 family accounting for almost half of the total miRNA content (20). Other miRNA families highly represented in human platelets include miR-199, miR-103, miR-25, and miR-140. However, the expression of miR-223 was only ranked the tenth in this study. Overall, the top 15 miRNAs accounted for more than 90% of all miRNAs present in human platelets. More recently, Bray et al. analyzed miRNAs content in purified platelets from four healthy volunteers, expanding the number of known platelet miRNAs to approximately 750 (35). In their study, the top five miRNAs expressed most abundantly in platelets were miR-223, miR-451, miR-21, miR-23a, and miR-126. In Table 1, we summarized the top 20 miRNAs in platelet.

MicroRNAs and Platelet Biogenesis
Platelets are derived from megakaryocytes, and formed when the edges of mature megakaryocytes break off. Each megakaryocyte releases about 1,000ñ5,000 platelets (40, 41). The process of platelet production lasts approximately 7 days, involving in three main phases: megakaryocyte differentiation, megakaryocyte maturation, and platelet formation. This process is complex and regulated by multiple mechanisms including epigenetic, transcriptional as well as post-transcriptional gene

---

**FIGURE 1** Proposed model for the inheritance and operation of platelet miRNAs. On the one hand, platelets inherit precursor miRNA (pre-miRNA) from megakaryocytes and process them into mature miRNA by Dicer. On the other hand, platelets also inherit mature miRNA from megakaryocytes, and absorb miRNA from endothelial cells and leukocytes.
expression control. Indeed, several studies have addressed miRNAs as well as their target proteins play important roles in megakaryocytopoiesis and platelet biogenesis (Figure 2; 21, 22, 29, 42).

In the megakaryocytopoiesis stage, hematopoietic stem cells (HSCs) differentiate and grow into megakaryocyte erythroid progenitor cells (MEPs) in bone marrow, which then develop to megakaryocytes under the influence of different factors such as thrombopoietin (TPO). Garzon et al. firstly explored the differential expression of miRNAs profiles between cultured CD34+ hematopoietic progenitor cells and megakaryocytes (43). They found a strong downregulation of 19 miRNAs during megakaryocytopoiesis suggesting that these downregulated miRNAs possibly unblock certain genes involving this process. For example, MAFB (v-maf musculoaponeurotic fibrosarcoma oncogene homolog B) and HOXA1 (Homeobox A1) gene are upregulated during megakaryocyte differentiation, as they are targets for the downregulated miR-130a and miR-10a, respectively (43). In contrast, miR-34a increases during megakaryocytic differentiation and stimulates megakaryocytopoiesis by enhancing megakaryocyte colony formation from CD34+ hematopoietic progenitor cells and megakaryocytes (43). Additionally, hematopoietic stem cells with miR-150 overexpression produced 8-fold enrichment of megakaryocyte in vitro and 15-fold amplification in vivo compared with normal controls. miR-150 was shown to maintain normal differentiation of MEPs into megakaryocyte by targeting the transcription factor c-myb (45). On the contrary, miR-28 attenuates TPO stimulating signal by downregulating the thrombopoietin receptors (TPOR, MPL), leading to a negative effect on megakaryocyte differentiation (46). Recently, other miRNAs such as miR-10a, miR-155, and miR-125a-5p were also shown to play an important role in the formation of megakaryocytes (47–49). Interestingly, mature platelets release microvesicles (PMVs) containing many miRNAs can be internalized by bone marrow hematopoietic stem cells and regulate megakaryocytes biogenesis as a self feedback regulatory mechanism (50, 51). MiR-223, the most abundant miRNA in PMVs, enhances MK differentiation and maturation by inhibiting MYH10 and LMO2 (52). Additionally, global miR-223 knockout leads to an obstacle in the recovery of platelet production after platelet immunodepletion in mice, supporting the role of miR-223 in thrombopoiesis (53). Another miRNA, miR-1915-3p, which is highly enriched in PMV, exhibits more significant effects than miR-223 in promoting MK differentiation by suppressing Rho GTPase family member B (RHOB) expression (54).

In the thrombopoiesis stage, megakaryocytes greatly enlarge their bodies with amplifying their DNA to 64-fold, filling with a high concentration of ribosomes, and synthesizing lots of platelet-specific proteins (55–57). Then, an expansive and interconnected membranous network of pools and tubules is formed, also named the demarcation membrane system (DMS) (58). DMS divides the megakaryocyte cytoplasm into small chamber where pro-platelets are split out (59, 60). TPO is widely regarded as the primary regulator of thrombopoiesis for their promoting roles on megakaryocyte endomitosis by binding to the c-Mpl receptor (61, 62). MiR-204-5p and miR-28a were reported to directly target TPO and MPL, respectively, via sequence-dependent 3′-UTR repression and inhibit platelet formation (46). Additionally, miR-142-3p was reported to maintain actin filament homeostasis, thereby promoting actin-dependent pro-platelet formation (63). miR-125a-5p directly targets and reduces the expression of L-plastin, an actin-bundling protein who inhibits the pro-platelet formation (49). Other miRNAs, such as miR-125b and miR-660 were found to promote platelet output from cultured megakaryocytes while miR-23a/27a/24-2 cluster blocked this process (64).

### Platelet MicroRNAs and Platelet Activation

Platelets are unstable and keep hyperresponsiveness to external stimuli, such as endothelial injury, infection, and metabolic disorders. Platelet receptors, such as glycoprotein (GP Ib and GPVI), adenosine receptors (P2Y12 and P2Y1), thromboxane a2 receptor (TP), and thrombin receptors (PAR1, PAR3, and PAR4), act as switches for platelet activation once binding to their ligands von Willebrand factor (vWF), collagen, ADP, TXa2, and thrombin (65, 66). MiRNAs, as an important part of post-transcriptional regulation of platelet proteins, regulate platelet activity by directly targeting several platelet proteins (Table 2). Landry et al. firstly reported that Ago2-miR-223 complexes negatively regulated the expression of P2Y12 receptor by targeting the 3′-UTR region (27). However, the...
results of studies assessing the effect of miR-223 on platelet activation are contradictory. Leierseder et al. found that miR-223 did not affect platelet activation and aggregation and bleeding time while Elgheznawy et al. reported that miR-223 deletion in mice exacerbated platelet aggregation and the formation of large thrombi (53, 67). Additionally, miR-126 transfection inhibits platelet reactivity by downregulating the expression of a disintegrin and metalloproteinase-9 (ADAM9), a protease associated with the interaction between platelet adhesion and collagen, and P2Y12 receptor expression (68, 69). In a LPS-induced sepsis model, platelet miR-26b is significantly downregulated, which contributes to elevated P-selectin (SELP) expression of MKs and platelets, and augments platelet activation (70). MiR-181a targets Ras-related protein 1B (RAP1B), an important protein participating in platelet activation and hemostasis induced by agonists, and thereby reducing platelet activation (71). Recently, high-throughput RNA sequencing was used to compare miRNA and mRNA profiles between hypo- and hyper-reactive platelets and helped to discover more miRNA-mRNA pairs associated with platelet activation. Nagalla et al. reported that 74 miRNAs were significantly changed in epinephrine-activated platelets compared with resting subjects. Several changed miRNAs were negatively correlated with the genes related to platelet activation, such as miR-200b: PRKAR2B, miR-495: KLHL5, and miR-107: CLOCK. The regulatory relationship was validated by miRNA-mediated inhibition of the targeted genes. Moreover, the function of these miRNA-mRNA pairs was further confirmed by reduced activation in platelets lacking PRKAR2B (72).

**Platelet MicroRNAs and Platelet Secretion**

Platelets contain three types of secretory organelles—alpha and dense granules and lysosomes. Alpha granules are the largest and most abundant secretory granules in platelets. More than 280 proteins are stored in alpha particles, including vWF, PF4, P-selectin, and platelet-derived growth factor (PDGF) (73, 74). Dense granules contain more than 200 small molecules, mainly including calcium, ADP/ATP, and 5-hydroxytryptamine (75).
Lysosomes only account for a small proportion in platelet and have more heterogeneous in composition and properties, containing a number of acid hydrolases, cathepsins, and lysosomal membrane proteins (76). In addition, a large number of miRNAs may also be stored in these granules, since the circulating platelet-derived miRNA increases significantly, when these particles are secreted after platelet activation (36). However, what we still don’t know is their distribution and content in these particles.

The release of platelet granules is the material basis of platelet functional diversity and involves in the occurrence and development of many diseases especially cardiovascular and oncologic diseases (77). These platelet granules can fuse to the membrane of platelets via complex mechanisms after platelet activation and release their contents into the extracellular vascular space (78–82). The molecular mechanisms about platelet secretion mainly involve in soluble N-ethylmaleimidesensitive factor attachment protein receptor (SNARE) families (83). In 2010, Kondkar et al. reported that miR-96 overexpression resulted in significant inhibition of the expression of vesicle-associated membrane protein 8 (VAMP8), a SNARE protein which was elevated in hyperactive platelets and crucial for promoting platelet granules secretion (Table 2). In addition, miR-376c was found to inhibit the expression of phosphatidylinositol transfer protein (PCTP), an important protein contributing to secretion of dense granules by regulating PAR4-mediated platelet activation (84). Notably, the above-mentioned miRNAs who are involved in regulating platelet activation may also alter platelet particles secretion theoretically, since platelet exocytosis are initiated by platelet activation.

### Platelet Secretes and Delivers MicroRNAs

In earlier studies, researchers found that the changes of circulating miRNA were closely related to platelets activation. They identified a large number of miRNAs when comparing the miRNA profiles in hyporeactive platelets and hyperreactive ones in response to agonist stimulation (72). However, what puzzles scientists is how they are released and maintain their stability after entering into circulation? In the past, the concept that platelets produce many membrane encapsulated extracellular vesicles (EVs) has been widely accepted (74, 85). These EVs hide miRNAs in their natural membrane barrier and isolate them from degradative components (such as nucleases) in the extracellular environment, maintaining the stability of extracellular miRNAs. Later, researchers demonstrated that platelet secreted miRNAs into circulation possibly through EVs-mediated manner (86, 87). They compared miRNAs profiles between plasma microparticles (MP) and MP-free plasma and confirmed that plasma miRNAs mainly originated from microparticles. 41–45% of circulating microparticles were of platelet, 28% of leukocyte, and 8% of endothelial origin.

Upon stimulation, platelets mainly secrete two types of EVs: exosomes (derived from exocytosis of multivesicular bodies and alpha-granules, <100 nm) and microvesicles (produced by surface shedding, 100 nm–1 μm) (74). Although exosomes from endothelial cells and tumor cells have been verified to be carriers for miRNA-based intercellular communication and a source of circulating miRNAs (88), the role of platelet-derived exosomes in miRNA transfer is still undetected. Philipp Diehl et al. firstly proposed that circulating miRNAs were mainly localized in microvesicles (MVs) derived from different tissues, especially from platelets (87). Consistently, Laffont et al. reported that platelet-derived microvesicles (PMVs) acted as intercellular transporters delivering rich miR-223 to endothelial cells and altering the gene expression (86). Thus, the transfer of platelet miRNAs is mainly mediated by PMVs (89). Indeed, platelet-derived MVs are the major source of cell-derived MVs in the circulation (90), which is consistent with the conclusion that circulating miRNAs are mainly platelets-derived (91). Then, we elaborate on the regulation of PMVs mediated miRNAs on distant cells below (Figure 3).

### Platelet Microvesicles Transfer MicroRNAs to Endothelial Cells

Takeuchi et al. found that platelet-like particles (PLPs) derived from the megakaryoblastic cell line Meg-01 transferred labeled RNA to the endothelial recipient cells. This is the first evidence supported the phenomenon of platelet-mediated miRNA transfer (92). Later, Laffont et al. found that endothelial cells actively uptake PMVs produced by activated platelets, resulting in a significant increase of platelet miRNA (such as miRNA-223) in HUVECs when they are co-incubated. Moreover, miR-223-Ago complexes in PMVs was found to have regulatory ability,
Platelet MPs mediate the transfer of intercellular miRNAs to other cells in the circulatory system, and participate in the regulation of gene expression of recipient cells. MPs released by activated platelets are rich in bioactive lipid mediators, cytokines, miRNAs and a wide variety of non-coding RNAs (including miRNAs). Platelet-derived miRNAs can be efficiently transferred into endothelial cells, immune cells, and cancer cells through MPs-mediated manner. Platelet MPs form a tent to protect miRNAs from extracellular nucleases degradation and act as intercellular transporters to deliver functional Ago2-miRNA complexes, through which they modulate the genes of recipient cells in the circulatory system and perform a wide range of biological functions. The red represents miRNA-mRNA pairs that produce promoting functions and the blue represents miRNA-mRNA pairs that produce inhibitory functions. Abbreviations: Ago2, argonaute 2; ATF3, activating transcription factor 3; ATP1B1, sodium/potassium-transporting ATPase subunit beta-1; ATP9A, ATPase phospholipid transporting 9A; RAI14, retinoic acid induced 14; VEGFA, vascular endothelial growth factor A; FBXW7, F-box and WD-40 domain protein 7; EFNA1, ephrin A1; IGF1-R, insulin like growth factor 1 receptor; ICAM-1, intercellular adhesion molecule 1; SELP, selectin P; PDGFRα, platelet derived growth factor receptor alpha; TSP-1, thrombospondin 1; BCLAF1, BCL2 associated transcription factor 1; EPB41L3, erythrocyte membrane protein band 4.1 like 3; mt-Nd2, mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2.

resulting in significant downregulation of the expression of two endogenous target genes FBXW7 and EFNA1 (86). Consistently, increased miR-223 in thrombopoietin-induced platelets leads to decreased IGF1-R expression in cultured endothelial cells, and exacerbates their apoptosis (93). Additionally, platelet-derived miR-223 also was predicted to target the ICAM-1 gene and proved to inhibit its expression in HUVECs during inflammation process via blocking the NF-κB and MAPK pathways (94). Besides miR-223, co-culture of fluorescent labeling platelets with miR-Scr-FITC and HMEC-1 endothelial cells confirms that 4 platelet-derived miRNAs (miR-22, −185, −320b, and −423-5p) are uptake by endothelial cells and restrains the expression of ICAM-1 (23). Moreover, miR-96 and −26a were also found to be transferred from PMVs to HUVECs, and inhibited the migration
and tube formation of HUVECs (95). In conclusion, platelet-derived miRNAs are taken up by endothelial cells through microvesicles, inhibit endothelial inflammation, migration and tube formation, and promote apoptosis. However, the opposite results also exist. Let-7a highly expressed in PMVs was found to significantly promote endothelial cell angiogenesis by targeting the anti-angiogenic molecule thrombospondin-1 (TSP-1) (96). Moreover, miR-142-3p from PMVs was also found to be delivered into endothelial cells and enhanced their proliferation via inhibiting the expression of Bcl-2-associated transcription factor (BCLAF1) (97). Therefore, the effects of platelet-derived miRNAs on endothelial cells depend on the type of miRNA ingested. However, it is still unclear whether the uptake of platelet-derived miRNA types by endothelial cells is selective in different states, or only depends on the content of miRNAs in PMVs. It is worth noting that SMCs are identified as other recipients on vascular for PMV-mediated miRNAs. Thrombin-stimulated platelets produced numerous PMVs containing miR-223, miR-339, and miR-21, which were transferred into SMCs and inhibited their proliferation by downregulating the expression of platelet-derived growth factor receptor beta (PDGFRb) (98).

**Platelet Microvesicles Transfer MicroRNAs to Immune Cells**

Circulating leukocytes are a kind of cells that can be directly coupled with activated platelets through surface receptors, and subsequently modifying their phenotypes. In this study, we focused on leukocytes as recipient cells that receives miRNAs from PMVs and the biological effects of the miRNAs on the former. Laffont et al. found that fluorescently labeled PMVs were internalized by primary human macrophages when they were co-incubated, subsequently causing the aggregation of miR-126-3p in the recipient macrophage (99). Further analysis using transcriptome-wide microarray, 34 miRNAs were identified to be significantly elevated in macrophages upon incubation with PMVs. Correspondingly, 367 mRNAs, including important cytokines and chemokines such as CCL4, CSF1, and TNF-α, acting as potential targets for these changed miRNAs, were confirmed to be significantly downregulated. Co-incubation of macrophages with PMVs enhanced their ability of phagocytosis, pointing toward a potential role of PMVs-mediated miRNAs in shaping macrophage functions (99). However, it didn’t identify which miRNAs besides miR-126-3p are involved in the cellular reprogramming of macrophages. A later study from Yang et al. suggested that mRNA-4306 mainly from PMVs was effectively delivered into human monocyte-derived macrophages, and inhibited their migration in vitro and reduced macrophage infiltration in myocardial infarction tissues. The inhibitory effect of miR-4306 on macrophages was possibly mediated by restraining the ERK/NF-kB signaling (100). Besides macrophages, PMVs also interact with natural killer (NK) cells and shift their function via transferring platelet-derived miR-183 and suppressing the expression of NK activation adapter DAP12 (101). However, the mechanisms of PMV-miRNAs transfer and mediated gene regulation on other immune cells require further exploration.

**Platelet Microvesicles Transfer MicroRNAs to Cancer Cells**

Although the role of PMVs in tumor regulation has been largely confirmed, there are few studies on whether the miRNAs carried by PMVs have direct effects on tumor cells (102). In 2015, Liang et al. found that PMVs-derived miR-223 was rapidly delivered into human lung cancer A549 cells once they were nurtured together. Subsequently, the invasion ability of A549 cell was increased. This effect may be explained by the inhibition of tumor suppressor-associated gene EPB41L3 by platelet miR-223 in A549 cells (103). By contrary, Michael et al. reported that platelet-derived RNAs, including miRNAs, were transferred into tumor cells, leading to tumor cell apoptosis as their vector PMVs left the circulation and entered the tumor microenvironment. MiR-24 was a major species in this transfer (104). These findings provide novel insights of horizontal miRNA transfer from PMVs to tumor cells and their roles on cancer progression. However, the mechanisms of PMVs infiltration and miRNA transfer, as well as the types of transferred miRNAs and global effects on tumor gene expression, remain to be further investigated.

**Functions of Platelet-Derived MicroRNAs in Cardiovascular Diseases and Cancer**

For the past few decades, platelet hyperactivation had been elaborated to play important roles in the development and progression of cardiovascular diseases and cancer (105–107). Activated platelets release a variety of vasoactive substances, cytokines and growth factors, promoting platelet-leukocytes crosstalk, mediating the migration of leukocytes, and inducing smooth muscle cell migration and proliferation, further aggravating the damage of vascular-related diseases (108). Platelet secretion also plays multiple roles in cancer fate, including promoting proliferation, resisting cell death, inducing angiogenesis, accelerating invasion and metastasis, and evading immunodetection (109). Activated platelets release and deliver abundant miRNAs as above mentioned; however, few studies have systematic revealed their association and value with clinical diseases. Here, we will explore the possible association of platelet-derived miRNAs with cardiovascular disease and cancer (Tables 3, 4 and Figures 4, 5).

**Platelet-Derived MicroRNAs and Atherosclerosis**

Atherosclerosis (AS) is a chronic cardiovascular disease that underlies the pathology of cerebral infarction and coronary heart disease (110). The occurrence and development of AS involve in a series of pathological and physiological processes, mainly including vascular endothelial damage, inflammatory cell and lipid infiltration, platelet activation, and intimal thickening (111–113). Platelets are considered to be important contributors to atherosclerosis for their ability to induce inflammatory cascades. Activated platelets lead to vascular damage through the expression and release of inflammatory mediators and promote the activation and degeneration of endothelial cells to form atherosclerosis and vascular thrombotic lesions (114). They also promote intercellular communication and adhesion between blood cells and the vessel wall, proliferation of SMCs and chemotaxis of foam cells (115, 116).
TABLE 3 | The potential roles of platelet miRNAs on cardiovascular diseases and diabetes.

| Diseases        | MicroRNA | Target                      | Associated phenotypes                                                                 | References |
|-----------------|----------|-----------------------------|--------------------------------------------------------------------------------------|------------|
| Atherosclerosis | miR-21   | MAP3K10                     | Inhibit macrophage inflammation and atherosclerosis progression                      | (119)      |
|                 | miR-223  | ICAM-1, NFAT5               | Inhibited endothelial inflammation and intra-arterial thrombosis in atherosclerosis; inhibited proliferation and migration of SMCs and atherosclerosis progress | (94)       |
|                 | miR-34a  | Sirt1                       | Aggravated atherosclerotic plaque development                                         | (121)      |
|                 | miR-25-3p| Adam 10                     | Inhibited ox-LDL-induced vascular endothelial inflammation, lipid deposition, and atherosclerosis | (123)      |
|                 | miR-22-3p| HMGB1                       | Suppressed the proliferation and migration of SMCs, and neointimal hyperplasia during atherosclerosis | (236)      |
|                 | Let-7g   | PDGF/MEKK1                  | Decreased atherosclerotic plaques                                                     | (237)      |
|                 | Let-7    | IL-6/TGFR1                  | Reduced diabetes-associated carotid atherosclerosis                                   | (155)      |
| Myocardial infarction | miR-22-3p| PTAFR                       | Suppressed the fibrogenesis and collagen deposition of post-MI                         | (238)      |
|                 | miR-4306 | VEGFA                       | Reduced macrophage infiltration in cardiac tissue in myocardial infarction mice        | (100)      |
|                 | miR-320b | ICAM-1                      | Alleviated endothelial inflammation in myocardial infarction mice                      | (23)       |
|                 | miR-223-3p| KLF15, PPAR-1, RASA1       | Protected cardiomyocyte from hypoxia-induced apoptosis and oxidative stress; promoted the proliferation, migration, and differentiation, and aggravated myocardial fibrosis | (129)      |
|                 | miR-126  | HIF-1α, VEGFA               | Promote angiogenesis in AMI patients                                                  | (129)      |
| Hypertension    | miR-142-3p| BCLAF1                     | Promoted endothelial cell proliferation in hypertension                                | (97)       |
|                 | miRNA-126| PI3KR2                      | Prevented microvascular abnormalities in hypertension                                  | (134)      |
|                 | miR-140-5p| Nrf2/Sirt2                 | Lowered blood pressure and weakened reduced organ damages in hypertension              | (241)      |
| Diabetes        | miR-223  | P2y12R, SMOC1, NLRP3, FOXO1/SOX6, GLUT4 | Restained platelet hyperreactivity associated with diabetes; inhibited endothelial injury induced by high-glucose and high-fat; promoted β-cell proliferation and improved β-cell function in diabetes; Increased glucose metabolism of cardiomyocytes and improved diabetic cardiomyopathy | (245)      |
|                 | miR-126  | ADAM9                       | Rescued diabetes-induced impairment in effectorcytosis of apoptotic cardiomyocytes     | (246)      |
|                 | miR-140  | FOXK2                       | Improved angiogenic dysfunction in diabetes mellitus                                   | (246)      |
|                 | miR-143  | OP8                         | Inhibited insulin-stimulated AKT activation and impaired glucose metabolism            | (247)      |
|                 | miR-103b | SFRP4                       | Early diagnosed DM2                                                                  | (148)      |

ICAM-1, intercellular adhesion molecule 1; NFAT5, nuclear factor of activated T cells 5; Adam 10, a disintegrin and metalloprotease 10; HMGB1, high mobility group box 1; PDGF, platelet-derived growth factor; MEKK1, mitogen-activated protein kinase kinase kinase 1; TGFR1, transforming growth factor receptor 1; PTAFR, platelet-activating factor receptor; VEGFA, vascular endothelial growth factor A; KLF15, kruppel like factor 15; PPAR-1, poly (ADP-ribose) polymerase 1; RASA1, RAS p21 protein activator 1; BCLAF1, BCL2-associated transcription factor 1; P3KR2, phosphomannoside-3-kine regulatory subunit 2; Nrf2, nuclear factor erythroid 2-related factor 2; Sirt2, sirtuin 2; HDAC8, histone deacetylase 8; ADRA2B, norepinephrine receptor 2; NLRP3, nod-like receptor protein 3; FOxO1, forkhead box O1; SOX6, SRY-box transcription factor 6; GLUT4, glucose transporter 4; FOXK2, forkhead box K2; ORP8, oxysterol-binding protein-related protein 8; SFRP4, secreted frizzled related protein 4.

As mentioned above, platelet-derived miRNAs not only regulate platelet function, but also participate in endothelial cell function and SMC proliferation, suggesting that they may play a significant role in the occurrence and development of atherosclerosis. Several studies have found platelet-derived miRNAs changed in the circulation of atherosclerotic patients. In a study performed by Sondermeijer group, circulating miR-624 and miR-340 are found to be significantly elevated in patients with CAD as compared to healthy controls (117). However, the expression of miR-126 and miR-223 in platelets were reduced in AS patients. Among them, miR-126 expression level was proven to have a negative correlation with plaque morphology and coronary stenosis (118). The mechanism may involve the targeted regulation of MAP3K10 by miR-21 to inhibit macrophage inflammation and atherosclerosis progression (119). In a atherosclerosis animal model, more miRNAs such as miR-19a, −21, −126, −26b, −92a, −155, −204, −210, −221, −222, and −34a are reported to be delivered by PMVs and contribute to the richness of circulating miRNAs (120). Elevated miR-34a aggravated atherosclerotic plaque development by inhibiting Sirt1 signaling in an atherosclerosis mouse model (121). Other demonstrated the roles of platelet-derived miRNAs in many key links of atherosclerosis development. MiR-223 released by thrombin-activated PMVs inhibits ICAM-1 expression by regulating NF-κB and MAPK pathways and is protective against atherosclerosis and endothelial inflammation (94). MiR-223 also inhibits the platelet-derived growth factor-BB (PDGF-BB)-induced proliferation and motility of human aortic smooth muscle cells by targeting NFAT5 and exhibits potential therapeutic effects for atherosclerosis (122). Platelet-derived...
exosomes overexpressing miR-25-3p attenuate coronary vascular endothelial cell inflammation induced by oxidized low density lipoprotein via targeting NF-κB/Adam10 Pathway in ApoE-/mouse models of atherosclerosis (123). However, whether other differentially expressed platelet miRNAs are also involved in the occurrence and development of atherosclerosis remains unclear.

### Platelet-Derived MicroRNAs and Myocardial Infarction

The rupture of unstable plaque leading to rapid activation and aggregation of circulating platelets, and following thrombosis, is the main mechanism of myocardial infarction. Several selected platelet miRNAs were found to significantly change in acute myocardial infarction (AMI) and become indicators of thrombosis. Candidate platelet miR-21 and miR-126 were significantly descended in patients with AMI compared with the controls while the results of platelet miR-150 and miR-223 were opposite. Hromadka et al. found that miR-126 and miR-223 were potential independent predictors of thrombotic events and recommended for ischemic risk stratification after AMI (124). The expression levels of platelet miR-587 were relatively higher in AMI patients than unstable angina (UA) and control groups and showed positive association with the degree of coronary stenosis (125). These results suggest that platelet-derived miRNAs may induce atherosclerotic plaque instability or thrombosis besides platelet function. Elghenzawy et al. found that in a mouse FeCl3-induced arterial thrombosis model, miR-223 deficiency increased thrombus size after FeCl3 carotid treatment, and increased embolization after laser-induced vascular injury of the small dorsal skin (67). MiR-223 directly targets kindlin3, an integrin-binding protein, and FXIII-A, both of which contribute to thrombus formation. Therefore, platelets unexpectedly antagonize the formation of thrombi by releasing specific miRNAs, such as miR-223, when they are abnormally activated in the early stage of MI, through above mechanisms. Additionally, miR-223 has also been found to exhibit contradictory direct cardiac effects in myocardial infarction, including protecting cardiomyocytes from ischemic injury, promoting fibroblast proliferation and collagen formation (126–128). Of course, platelet miRNAs also influence platelet activity by targeting its surface receptors, such as miR-223/P2Y12 and miR-126/Adam9, accounting for their potential behaviors during thrombosis (27, 68). Besides, inflammatory response accelerating myocardial fibrosis after myocardial infarction is closely related to the deterioration of cardiac function and long-term prognosis. MiR4306 from PMVs noticeably inhibited macrophage infiltration in cardiac tissue in myocardial infarction mice, which may also restrain the progression of post-infarction remodeling (100). Endothelial cells expressing ICAM-1 triggering the adhesion and migration of inflammatory cells to the damaged myocardium, has been found to be regulated by platelets releasing miR-320b (23) and miR-223 (122). Additionally, exosomes containing miR-126 extracted from AMI patients promote angiogenesis by increasing HIF-1α and VEGFA expression (129).

### Platelet-Derived MicroRNAs and Hypertension

Hypertension is a complex, multifactorial disease, and its occurrence and development have definite relationships with miRNA regulatory network (130). Marketou et al. assessed platelet-derived miRNAs in 82 patients with essential hypertension and 28 healthy individuals and found that miR-22 and −223 levels are significantly decreased in hypertension and negatively correlated with SBP levels (131). Additionally, let-7 is reported to have a positive correlation with carotid intima-media thickness in patients with essential hypertension (132) while miR-21 has a negative association with arterial stiffness (133). These results suggest that platelets are involved in the formation and progress of hypertension by delivering miRNAs, although the mechanisms seem not very clear. Abnormal proliferation of endothelial cells (EC) induced by pathologic factors contributes to vascular remodeling in hypertensive conditions. MiR-142-3p from PMVs enhanced EC proliferation by downregulating the expression of BCLAF1 (97). In a spontaneously hypertensive rat (SHR) model, miRNA-21 levels were increased by 36% levels while miRNA-126 levels were reduced by 29%. Both of them are abundant in platelets. Aerobic exercise training reversed their changes and prevented microvascular abnormalities in hypertension via increasing the expression of anti-apoptotic protein Bcl-2 and inhibiting the expression of anti-angiogenic regulator PI3KR2 (134). Thus, regulating endothelial cell proliferation in hypertensive vascular remodeling is one of the mechanisms to explain the potential

---

**TABLE 4 | The potential roles of platelet miRNAs on cancer.**

| MicroRNA | Target          | Associated phenotypes                          | References |
|----------|-----------------|------------------------------------------------|------------|
| miR-223  | Meflo2c         | Promoted lung cancer cell invasion             | (168)      |
|          | RhoB            |                                                 | (169)      |
|          | EPB41L3         |                                                 | (103)      |
| miR-126  | VEGF-A          | Inhibit the progression of ovarian cancer       | (172)      |
|          | ZEB1            | Inhibit the progression of ovarian cancer       | (173)      |
|          | ADAM9           | Inhibit the progression of ovarian cancer       | (174)      |
|          | CCR1            |                                                 | (175)      |
| miR-24   | mt-Nd2          | Induced growth of both lung and colon carcinoma | (104)      |
| miR-939  | E-cadherin      | Induced breast cancer metastasis to the brain   | (178)      |
| miR-22   | ACLY            | Inhibited the growth and metastasis in breast cancer, inhibits the angiogenic activities of endothelial cells and consequently NSCLC growth | (180) |
|          | SIRT1/FGFR1     | Inhibited the growth and metastasis in breast cancer, inhibits the angiogenic activities of endothelial cells and consequently NSCLC growth | (187) |
| Let-7d   | HIF1α           | Inhibited breast cancer metastasis to the brain | (248)      |
| miR-27b  | THBS-1          | Enhanced the pro-angiogenic activities         | (168)      |
| miR-21   | KRIT1           | Leading to tumor progression                    | (182)      |
|          | PTEN            | Leading to tumor progression                    | (183)      |
| miR-142  | TGF-β           | Leading to decreased growth and metastasis of hepatocellular carcinoma by antagonizing angiogenesis | (186) |

HIF1α, hypoxia inducible factor 1 subunit alpha; VEGF-A, vascular endothelial growth factor A.

---

**Platelet-Derived MicroRNAs and Hypertension**

Hypertension is a complex, multifactorial disease, and its occurrence and development have definite relationships with miRNA regulatory network (130). Marketou et al. assessed platelet-derived miRNAs in 82 patients with essential hypertension and 28 healthy individuals and found that miR-22 and −223 levels are significantly decreased in hypertension and negatively correlated with SBP levels (131). Additionally, let-7 is reported to have a positive correlation with carotid intima-media thickness in patients with essential hypertension (132) while miR-21 has a negative association with arterial stiffness (133). These results suggest that platelets are involved in the formation and progress of hypertension by delivering miRNAs, although the mechanisms seem not very clear. Abnormal proliferation of endothelial cells (EC) induced by pathologic factors contributes to vascular remodeling in hypertensive conditions. MiR-142-3p from PMVs enhanced EC proliferation by downregulating the expression of BCLAF1 (97). In a spontaneously hypertensive rat (SHR) model, miRNA-21 levels were increased by 36% levels while miRNA-126 levels were reduced by 29%. Both of them are abundant in platelets. Aerobic exercise training reversed their changes and prevented microvascular abnormalities in hypertension via increasing the expression of anti-apoptotic protein Bcl-2 and inhibiting the expression of anti-angiogenic regulator PI3KR2 (134). Thus, regulating endothelial cell proliferation in hypertensive vascular remodeling is one of the mechanisms to explain the potential
Leng et al. Functions of Platelet-Derived MicroRNAs

FIGURE 4 | Functions of platelet-derived miRNAs in cardiovascular diseases. The transport of miRNAs from platelet microvesicle (PMV) to the cardiovascular system participate in the occurrence and development of hypertension, diabetes, coronary heart disease, and myocardial infarction, involving multiple mechanisms such as endothelial homeostasis, smooth muscle cell proliferation, inflammatory cell infiltration, and cardiomyocyte apoptosis. Red labeled miRNAs promoted their downstream processes, while blue labeled miRNAs inhibited the downstream processes.

role of platelet-derived miRNAs. Additionally, PMVs from thrombin-stimulated platelets transferring miR-223, −339, and −21 into SMCs were shown to inhibit their proliferation by downregulating the expression of PDGFRb (98). However, whether their proliferation effects on SMCs is enough to change the phenotype of hypertension deserves further study.

Platelet-Derived MicroRNAs and Diabetes

Diabetes mellitus is a serious threat to human lifespan worldwide, resulting in a 2–4 times increase in mortality compared with non-diabetic subjects (135, 136). Cardiovascular complications are the leading cause of death from diabetes, accounting for 50–75% of deaths (137, 138). It has been widely accepted that diabetes are prone to pro-thrombic condition by increasing coagulation activity, impaired fibrinolysis, endothelial dysfunction, and platelet hyper-reactivity. Although the detail mechanism of hypercoagulable state in diabetes remain unclear, hyperactivation, and endothelial dysfunction observed in diabetes contribute to this pathological process (139). In 1993, Nomura et al. reported that platelets were activated in diabetic patients and the microparticles released from them also increased in plasma (140, 141). Activated platelets are able to modulate the function of ECs and SMCs, contributing to both the initiation and progression of atherosclerosis, and even the ensuing atherothrombotic sequelae (142, 143). Recently, it has been reported that platelets have been found to be a major source of circulating miRNAs and specific miRNAs from platelets changed in diabetes, suggesting that platelets-derived miRNAs may be potential predictive markers and therapeutic targets.

Fejes et al. reported that hyperglycemia suppresses miRNAs expression in platelets. They found the expression of miR-223, miR-26b, miR-140, and miR-126 in mature platelets had been significantly inhibited in T2DM subjects (144), which at least partly because hyperglycemia decreased platelet Dicer activity (145). Additionally, miR-26b and miR-140 showed direct target on the gene SELP and miR-223 and miR-126 inhibited the expression of P2Y12 in platelets (144, 146). Similarly, Elgheznawy et al. found human subjects and mice with diabetes showed decreased levels of platelet miR-142, miR-143, miR-155, and miR-223, which possibly related to the inhibition of Dicer enzyme. Using calpain inhibitors to prevent the loss of platelet Dicer in diabetic mice can save the decrease of platelet-miRNAs and increase their target genes (67). Besides miR-223, the expression of miR-146a was also downregulated...
FIGURE 5 | Functions of platelet-derived miRNAs in cancer. Platelet-derived miRNAs change tumor fates in two ways: on the one hand, PMVs transfer platelet miRNAs to vascular endothelial cells and are associated with enhanced tumor metastasis and cancer progression; on the other hand, PMVs can penetrate the blood vessels and enter the tumor microenvironment to directly transfer platelet miRNAs into tumor cells, thus regulating gene expression in tumor cells and tumor progression. The red represents miRNA-mRNA pairs that produce promoting functions and the blue represents miRNA-mRNA pairs that produce inhibitory functions. Abbreviations: THBS-1, anti-angiogenic protein thrombospondin-1; KRIT1, krev interaction trapped protein 1; PTEN, phosphatase and tensin homolog deleted on chromosome ten; TGF-β, transforming growth factor β; SIRT1, sirtuin 1; FGFR1, fibroblast growth factor receptor 1; Mef2c, myocyte enhancer factor 2C; STAT3, signal transducer and activator of transcription 3; ACLY, proto-oncogene ATP citrate lyase; VEGFR-A, vascular endothelial growth factor receptor A; ZEB1, zinc finger E-box binding homeobox 1; CCR1, chemokine (C-C motif) receptor 1.

by hyperglycemia intervention, resulting in subsequent platelet activation in patients with diabetes. Moreover, low level of miR-223 and miR-146a in patients plasma with diabetes increases the risk of ischemic stroke (147). Platelet-derived miR-103b is significantly downregulated and also suggested as a novel biomarker for the early diagnosis of T2DM (148). Additionally, decreased miR-30c level induced by hyperglycemia promotes thrombus formation in T2DM by increasing the expression of plasminogen activator inhibitor-1 (PAI-1) (149).

The change of platelet-derived miRNAs contributed to diabetes-associated vascular lesion. Endothelial dysfunction in patients with T2DM is well recognized, resulting in the vascular system susceptible to thrombotic and atherosclerotic effects (150). Recent plasma miRNA analysis confirmed that the downregulation of miR-126 in a group of diabetic patients are partially responsible for vascular damage in diabetic patients (151, 152). Elevated plasma miR-21 in diabetic patients was found to decrease the production of reactive oxygen species and inflammatory cytokines in vascular endothelial cells and reduce the area of atherosclerotic plaque by targeting the degradation of ADAM10 mRNA (153). Additionally, miR-223-3p improves the injury of cardiac microvascular endothelial cells from diabetic mice by targeting the expression of NLRP3 (154). Let-7, an abundant miRNA in PMVs, is decreased in human and mice carotid plaques with diabetes, and promotes the inflammatory phenotypes of SMCs including proliferation, migration, monocyte adhesion, and NF-κB activation (155).

Targeting platelet-derived miRNAs appears to confer some protective effects in diabetes. For example, aerobic training improves platelet function in type 2 diabetic patients via increasing miRNA-130a and decreasing the target gene GPIIb (156). Long-term moderate-intensity aerobic training increased miRNA-223 expression, leading to decreased expression of P2Y12 receptor and platelet activity, which may be one of internal
mechanisms for reducing the occurrence of atherothrombotic events in T2DM patients (157, 158). Additionally, inhibiting platelet activation by aspirin reduced levels of circulating miR-126 (159), which may protect endothelial from inflammation.

**Platelet-Derived MicroRNAs and Cancer**

Cancer is the leading cause of death following CVDs and shows close associations with CVDs. Tumors are often accompanied by overactive platelets and hypercoagulable state, as well as endothelial proliferation and angiogenesis in the tumor microenvironment, overlapping some pathogenesis with many cardiovascular diseases (160, 161). Long-term platelet inhibition in cardiovascular disease is considered to regulate tumor fate by alleviating chronic inflammation and endothelial angiogenesis (162, 163). Additionally, tumor therapy often leads to cardiovascular disease, which is well-known as cardiovascular oncology (164). Therefore, platelet function and its derived miRNAs may be the common markers for diagnosis and common targets for treatment about these two diseases.

In fact, platelets are active participants in all steps of tumorigenesis, including tumor growth, angiogenesis, and metastasis. On the one hand, PMVs transfer platelet miRNAs to vascular endothelial cells and are associated with enhanced tumor metastasis and cancer progression. On the other hand, due to the high permeability of the vascular system of solid tumors, PMVs can penetrate the blood vessels and enter the tumor microenvironment to directly transfer platelet miRNAs into tumor cells, thus regulating gene expression in tumor cells and tumor progression (164, 165). Subcutaneously implanted tumors with platelet miRNA knockout in mice aggravated sarcomatoid tumor progression (164, 165). MiR-223 directly targets the 3’UTR of many oncogenes and tumor suppressor genes. It has been verified the tumor-promoting effects of platelet miRNAs (167).

In different cancer cells, PMVs derived miRNAs target different oncogenes and tumor suppressor genes. It has been reported that miR-223 enhances breast cancer invasion by inhibiting the expression of myocyte enhancer factor 2C (MeF2c) and increases the progression of gastric cancer by specifically targeting RhoB (168, 169). It has also been reported that miR-223 directly targets the 3’-UTR of the tumor suppressor EPB41L3, which is the most upregulated gene in recurrent tumors (170). Increased miR-223 was observed in platelets and PMVs from NSCLC patients and effectively delivered to human lung cancer cell A549 via PMVs (103), thus facilitating the invasion of A549.

Physiological delivery of platelets miR-223 and miR-126 altered the phenotypes of breast cancer cells, including cell cycle arrest, migration inhibition, and increased responsiveness to cisplatin (171). MiR-126 can inhibit the progression of some cancers (including ovarian cancer, cervical cancer, prostate cancer, and NSCLC) via negative control of numerous validated targets such as VEGF-A, ZEB1, ADAM9, and CCR1 (172–175). In some instances, however, miR-126 supports cancer progression via inhibiting STAT3-mediated tumor apoptosis (176, 177). MiR-24 in PMVs inhibits the growth of ectopic tumors of lung and colon cancer by targeting mitochondrial protein mt-Nd2. Blocking miR-24 in tumor cells accelerates their growth in vivo and eliminates the inhibitory effect of PMVs on tumor growth (104). In ovarian cancer cells, miR-939 delivered by PMVs induces mesenchymal transformation of epithelial cells and cancer progression by inhibiting the expression of e-cadherin expression (178). In small-cell lung cancer (SCLC), overexpression of miR-24-3p blocked the autophagy process by targeting autophagy-associated gene 4A (ATG4A), finally enhancing the sensitiveness of SCLC cells to combined chemotherapy (etoposide and cisplatin) (179). In breast cancer, miR-22 inhibited the growth and metastasis by downregulating the expression of the proto-oncogene ATP citrate lyase (ACLY) (180). In solid tumors, PMVs interact with tumor cells by directly transferring platelet-derived miRNAs and inhibit the growth of ectopic tumors in colon and lung cancers by downregulating TC genes and inducing tumor cell apoptosis (104).

Platelet miRNAs also transfer to vascular endothelial cells and regulate tumor development and drug resistance by enhancing or inhibiting angiogenesis. When PMVs were co-cultured with HUVECs on extracellular matrix gels, PMVs-derived let-7a was adopted to endothelial cells and induced robust capillary like structure formation by promoting the release of pro-angiogenic regulators and reducing the expression of anti-angiogenic protein thrombospondin-1 (THBS-1) (96). In another in vitro experiment, THBS-1 expression was inhibited by transfection with elevated platelet miR-27b, which was subsequently enhanced the pro-angiogenic activities of platelet (181). Exosomal miR-21 in the tumor microenvironment had been widely known as a strong proangiogenic factor via targeting krev interaction trapped protein 1 (KRIT1) and PTEN (182, 183), finally leading to tumor progression. However, miR-223 is identified as an antiangiogenic miRNA by targeting β1 integrin (184), thereby promoting resistance to cetuximab in head and neck squamous cell carcinoma (185). Moreover, miR-142 was found to directly target and inhibit transforming growth factor β (TGF-β), leading to decreased growth and metastasis of hepatocellular carcinoma by antagonizing angiogenesis (186). MiR-22 also acts as a potent angiogenesis inhibitor that inhibits the angiogenic activities of endothelial cells and consequently NSCLC growth through targeting SIRT1 and FGFR1 (187).

**Platelet Inhibitors and Platelet-Derived MicroRNAs**

Antiplatelet drugs are considered as the cornerstone for the prevention and treatment of atherothrombotic diseases, and have saved numerous lives since inception. However, a considerable number of patients receiving standard antiplatelet medication still exhibit high levels of platelet activation, increasing their risk of progression and recurrence of cardiovascular events (188, 189). Several possible mechanisms were proposed to explain the phenomenon, such as genetic polymorphisms, drug–drug interactions, or high on-treatment platelet reactivity (HTPR) (190, 191). However, identifying patients who has inadequate response to state-of-the-art antiplatelet treatment remains a challenge. Thus, real-time monitoring of platelet activity seems to be more accessible and important for patients with atherothrombotic diseases and can ideally guide personalized antiplatelet treatment. Current platelet function tests are measured ex vivo and susceptible to interference by many
confounding factors, bringing obvious limitations for guiding treatment decisions. As mentioned above, platelet activation leads to the production of PMVs carrying abundant miRNAs, which in turn change platelet function and affect protein expression in other cells upon internalization. Antiplatelet drugs including COX inhibitors and P2Y12 receptor inhibitors were found to significantly change the expression of platelet-derived miRNAs (36, 192, 193). Circulating platelet miRNAs are relatively stable and convenient for detection in vivo, making them potential and reliable markers for monitoring platelet activity and antiplatelet response.

Willeit et al. firstly examined the responsiveness of platelet-derived miRNAs to platelet inhibition. They introduced that plasma levels of platelet miRNAs, including miR-126, miR-150, miR-191, and miR-223, are significantly reduced by aspirin and prasugrel treatment (91). Another recent study found that the levels of plasma miR-223 and miR-197 from platelets are significantly downregulated in subjects treated with clopidogrel or ticagrelor when compared with health controls (194). Acute coronary syndrome patients treated with clopidogrel alone resulted in 2-fold reduction in miR-223, 1.8-fold reduction in miR-130, and 4.1-fold reduction in miR-126 (195). Apparently, inconsistent miRNA alterations in different researches may be attributed to the kind of antiplatelet reagents, which results in varied degree of platelet inhibition. A recent study reported that plasma platelet miRNAs (such as miR-126, miR-150, and miR-223) were significantly reduced in ACS patients who completed the replacing treatment from clopidogrel to another more potent antiplatelet agent ticagrelor, in proportion to the degree of platelet inhibition (196). Additionally, monotherapy with potent P2Y12R inhibition prasugrel in T2DM reduced the levels of miR-24, miR-191, miR-197, and miR-223 when compared with aspirin treatment (197). Therefore, consensus on which miRNA is the best biomarker for the response to antiplatelet therapy has not yet been reached. Circulating miR-223 and miR-126 are expected to be the options since they reached similar conclusion in multiple studies (198–201).

Plasma level of platelet-derived miRNAs can also be used as a marker of antiplatelet insensitivity or resistance, also named high on-treatment platelet reactivity (HTPR). Kok et al. proposed that miR-19b-1-5p is a suitable marker of platelets insensitive to aspirin (202). MiR-365-3p is found to be positively correlated with HTPR in coronary artery disease patients (203). Additionally, platelets in ACS patients with HTPR exhibit upregulation of miR-204-5p after dual antiplatelet therapy (204). Lower expression of miR-126, miR-130, and miR-223 is also observed in the ACS patients with high platelet reactivity (HPR) to clopidogrel than those with low platelet reactivity (LPR) (195). A more recent study also reported that increased expression of miR-24-3p, miR-142-3p, and miR-411-3p was positively correlated with clopidogrel resistance (CR) in CAD patients (205). Similarly, miR-29, miR-34, miR-126, miR-142, and miR-223 are also reported to be novel biomarkers for P2Y12 inhibitor resistance prediction (206). Although the mechanisms of antiplatelet resistance are complex, the relationship between plasma miRNAs and platelet resistance may be explained by their regulation on platelet surface proteins. Liu et al. found that miR-34b-3p overexpression inhibited the expression of thromboxane A synthase 1 (TXAS1), leading to the enhanced antiplatelet efficiency of aspirin (207). The downregulated miR-107 and miR-223 in the HPR group are negatively correlated with P2Y12 expression, indicating that platelet miR-107 and miR-223 possibly mediated CR by inhibiting P2Y12 expression (208, 209). A more recent study also found that platelet miR-15b promoted platelet insensitivity in patients undergoing PCI because it suppressed Bcl-2 protein expression and enhanced platelet apoptosis (210).

In general, on the one hand, platelet-derived miRNAs are significantly altered by antiplatelet drugs and become potential indicators of platelet activity level. On the other hand, changes in platelet miRNA levels may in turn affect their response to antiplatelet drugs by altering the expression of platelet-activated receptors.

**Clinical Significances of Platelet-Derived MicroRNAs in Cardiovascular and Neoplastic Diseases**

As mentioned above, platelets are excessively activated in various vascular diseases, diabetes and tumors, and secrete many cell-specific miRNAs through PMVs. These miRNAs remain stable in peripheral blood, allowing a convenient detection, bringing them potential perspectives of early clinical diagnosis for platelet-related diseases (Table 5). Additionally, platelet miRNAs control and regulate the biological functions of themselves and other neighboring cells, participating in the occurrence and development of cardiovascular diseases and tumors, becoming novel potential targets for treatment.

**Platelet-Derived MicroRNAs as Potential Markers of Cardiovascular Diseases**

Considering the high mortality and morbidity of cardiovascular diseases and the lack of timely diagnosis, the discovery of novel predictive biomarkers is necessary. However, current diagnostic techniques based on electrocardiogram and troponin, are severely limited because they may be non-specifically altered in certain diseases, such as myocarditis and secondary myocardial damage. Platelet hyperactivation is another important clinical feature during acute thrombotic events (211), yet no corresponding test accurately reflects its states. Platelet-derived miRNAs have been reported to be biomarkers for platelet activation and are expected to be diagnostic and/or prognostic biomarkers for cardiovascular disease.

MiR-1, one of platelet-rich miRNAs, was found to increase rapidly and peak within 2 h after the onset of cardiac infarction and positively correlated with serum creatine kinase MB (CK-MB) levels (212). Another study showed that both increased miR-1 and miR-29b were associated with the decreased parameters of cardiac function (such as LVEDV and LVEF) in patients suffered AMI, indicating their potential predictive roles for adverse ventricular remodeling (213). MiR-126 and miR-223 were the most frequently investigated platelet miRNAs and it is well established that they are significantly reduced in CVD patients, making them an indication for the presence of cardiovascular
Therefore, the liquid biopsy is considered a promising tool for in space and time, and is not suitable for repeated sampling. From individual biopsies provides a limited snapshot of tumors and pathological analysis. Although biopsies are the current gold standard for cancer diagnosis, the information obtained and biochemical tests and radiological and clinical manifestations, predict prognosis, monitor response to treatment, and detect disease recurrence and metastasis.

Cancer diagnosis mainly depends on clinical manifestations, radiological and biochemical tests and pathological analysis. Although biopsies are the current gold standard for cancer diagnosis, the information obtained from individual biopsies provides a limited snapshot of tumors in space and time, and is not suitable for repeated sampling. Therefore, the liquid biopsy is considered a promising tool for early detection and subsequent monitoring of cancer. Platelets are an important component of blood, and their ability to store and release numerous miRNAs to the environment, which enables them to reflect different disease states, early diagnose tumors, predict prognosis, monitor response to treatment, and detect disease recurrence and metastasis.

Platelet miRNAs were significantly altered in tumor patients compared with healthy donors. For example, platelet-derived miR-223 was specifically overexpressed in NSCLC patients than healthy subjects. Additionally, tumor-educated platelet was reported to express higher levels of receiving miR-34c-3p and miR-18a-5p from nasopharyngeal carcinoma (NPC) cells, making them potential markers for NPC diagnosis. The positive rates for NPC diagnosis based on platelet miR-34c-3p and miR-18a-5p were 93.8 and 87.5%, respectively, significantly higher than these based on Epstein-Barr virus DNA (66.7%) (226). Moreover, a large prospective trial by Best et al. in 2015 showed that the RNA profile of tumor-affected platelets was different from that of healthy individuals, and identified the location of the primary tumor with 96% accuracy and 71% accuracy. Therefore, platelets and their derived miRNAs may be a potential source for the development of oncology blood biomarkers.

Platelet miRNAs can also be used to evaluate efficacy and patient outcomes. miR-21, miR-25, miR-19b, and miR-146a and in patients with NSCLC may be potential indicators to predict response to platinum-based treatments (228). Gasperi et al. reported that ω6/ω3-PUFA supplementation enhanced platelet antitumor activities by promoting PMVs derived miRNA (miR-223 and miR-126) delivery into breast cancer. These two miRNAs inhibited the cancer proliferation and metastasis and increased the sensitivity to cisplatin once internalized by breast cancer cells in a dose-dependent manner (171). Additionally, cardiovascular damage caused by tumor treatment contributes to the increasing mortality of cancer (229). Platelet-derived miRNAs may also become potential markers in the field of cardio-oncology. The levels of miR-223-3p decreased in radiation-induced heart in a time-dependent manner and exhibits potential protection against radiation-induced cardiac toxicity.

However, we still face many difficulties in trying to apply platelet miRNAs to the clinic. The primary problem is how to store and release numerous miRNAs to the environment, which enables them to reflect different disease states, early diagnose tumors, predict prognosis, monitor response to treatment, and detect disease recurrence and metastasis.

### TABLE 5 | Changes of platelet miRNAs in cardiovascular disease and cancer.

| Changed microRNAs | Disease | References |
|-------------------|---------|------------|
| miR-340†, miR815-5p†, miR-545-9.1†, miR-451†, miR-454†, miR-624†, miR-624†, miR-12801 † | Premature coronary artery disease | (117) |
| miR-150†, miR-223†, miR-21†, miR-126‡ | STEMI patients | (215) |
| miR-142-3p†, miR-107†, miR-338-3p†, miR-223-3p†, miR-21-5p†, miR-130b-3p†, miR-301a-3p†, miR-221-3p† | ACS patients | (219) |
| miR-186-5p†, miR-185-5p†, miR-200a-5p†, miR-942†, miR-127-3p†, miR-221-3p†, miR-483-5p†, miR-146a-5p† | Acute coronary syndrome | (249) |
| miR-150† | Heart failure with atrial fibrillation | (250) |
| miR-144†, miR-146a‡, miR-223‡ | Diabetes mellitus type 2 patients | (221) |
| miR-223† | with ischemic stroke | (147) |
| miR-34c-3p†, miR-18a-5p† | NSCLC patients | (103) |
| miR-223 | Nasopharyngeal carcinoma | (226) |

Platelet miRNAs are an important component of blood, and their ability to store and release numerous miRNAs to the environment, which enables them to reflect different disease states, early diagnose tumors, predict prognosis, monitor response to treatment, and detect disease recurrence and metastasis. Platelet miRNAs can also be used to evaluate efficacy and patient outcomes. miR-21, miR-25, miR-19b, and miR-146a and in patients with NSCLC may be potential indicators to predict response to platinum-based treatments (228). Gasperi et al. reported that ω6/ω3-PUFA supplementation enhanced platelet antitumor activities by promoting PMVs derived miRNA (miR-223 and miR-126) delivery into breast cancer. These two miRNAs inhibited the cancer proliferation and metastasis and increased the sensitivity to cisplatin once internalized by breast cancer cells in a dose-dependent manner (171). Additionally, cardiovascular damage caused by tumor treatment contributes to the increasing mortality of cancer (229). Platelet-derived miRNAs may also become potential markers in the field of cardio-oncology. The levels of miR-223-3p decreased in radiation-induced heart in a time-dependent manner and exhibits potential protection against radiation-induced cardiac toxicity.

However, we still face many difficulties in trying to apply platelet miRNAs to the clinic. The primary problem is how to store and release numerous miRNAs to the environment, which enables them to reflect different disease states, early diagnose tumors, predict prognosis, monitor response to treatment, and detect disease recurrence and metastasis.
on platelet miRNA. To avoid this problem, limiting miRNA measurements to PMVs has been recommended, but this would imply a greater workload and a more complex workflow. Future studies will need to explore convenient, economical and accurate detection methods.

**Treatment Prospect**

Alterations in tissue-specific or cell-specific miRNA expression and their regulation of pathogenic genes under different disease conditions provide a theoretical basis for the use of miRNA technologies to treat diseases. In the past few years, chemically modified oligonucleotides called antagonists have been developed to silence specific endogenous miRNAs in vivo and in vitro. Intravenous systemic administration of antagonists has been widely demonstrated to effectively and specifically recognize and inhibit the activity of target miRNAs in a sequence complementary binding manner in many cells. Several miRNA-targeted therapies have entered the stage of clinical development. For example, a mimetic tumor suppressor miR-34 has reached phase I clinical trials for the treatment of cancer. Additionally, a biological bead targeting miR-122 has entered the phase II trials for the treatment of hepatitis. However, drug delivery issues remain a barrier to their therapeutic use, particularly for targeting miRNAs in cardiovascular disease states. The properties of platelet endocytosis and transport of circulating RNAs have given us new solutions. Vesicle storage coupled with the relatively long half-life of miRNAs could allow miRNAs to persist in circulation for a long time, thus effectively silencing targets in various organ systems.

**CONCLUSION**

Overall, platelets are involved in several normal physiological processes such as hemostasis, inflammation, vascular repair, and generation, and play a role in diseases such as atherosclerosis, diabetes and cancer. Several studies have determined that activated platelets release miRNA-rich PMVs to regulate other cellular functions. With the intensive study of platelet-derived miRNAs, we realize that platelet miRNAs have the potential to be excellent diagnostic tools covering multiple pathological mechanisms simultaneously. Studies have shown that platelet miRNAs can directly or indirectly reflect platelet activity, thus indicating the emergence of pathological states at an early stage or assessing efficacy after treatment. We can also exploit the organ specificity of some miRNAs within platelets to enhance the effect of existing drugs or to find new therapeutic targets. In conclusion, studying platelet-derived miRNAs can be of great benefit to patients by helping to modify the use of existing drugs and finding new drug targets, as well as for assessing treatment efficacy and patient prognosis. Although there are still questions to be answered, platelet-associated miRNAs are promising biomarker candidates.

**AUTHOR CONTRIBUTIONS**

QL and LW wrote the manuscript, prepared the tables, and drew the figures. JD helped to process the figures. LW and YW designed the experiments, guided this study, and revised the manuscript. MD, LL, QF, and DW checked this manuscript. All authors contributed to this article and approved the submitted manuscript.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Grant Number: 81900244).

**REFERENCES**

1. Roth G, Mensah G, Johnson C, Addolorato G, Ammirati E, Baddour L, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. *J Am Coll Cardiol.* (2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010
2. Masaebi F, Salehi M, Kazemi M, Vahabi N, Azizmohammad Looha M, Zayeri F. Trend analysis of disability adjusted life years due to cardiovascular diseases: results from the global burden of disease study 2019. *BMC Public Health.* (2021) 21:1268. doi: 10.1186/s12889-021-11348-w
3. Roth G, Mensah G, Fuster V. The global burden of cardiovascular diseases and risks: a compass for global action. *J Am Coll Cardiol.* (2020) 76:2980–1. doi: 10.1016/j.jacc.2020.11.021
4. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. *JAMA Oncol.* (2019) 5:1749–68. doi: 10.1001/jamaoncol.2019.2996
5. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* (2011) 61:69–90.
6. Murphy S, Ibrahim N, Januzzi J. Heart failure with reduced ejection fraction: a review. *JAMA.* (2020) 324:488–504.
7. Hirsch F, Scaglotti G, Mulshine J, Kwon R, Curran W, Wu Y, et al. Lung cancer: current therapies and new targeted treatments. *Lancet.* (2017) 389:299–311.
8. Rowley J, Schwartz H, Weyrich A. Platelet miRNA: the meaning behind the message. *Curr Opin Hematol.* (2012) 19:385–91. doi: 10.1097/MOH.0b013e328357010e
9. Stojkovic S, Nossent A, Haller P, Jäger B, Vargas K, Wojta J, et al. MicroRNAs as regulators and biomarkers of platelet function and activity in coronary artery disease. *Thromb Haemost.* (2019) 119:1563–72. doi: 10.1055/s-0039-1693702
10. Estevez B, Du X. New concepts and mechanisms of platelet activation signaling. *Physiology (Bethesda).* (2017) 32:162–77. doi: 10.1152/physiol.0020.2016
11. Li Z, Delaney M, O’Brien K, Du X. Signaling during platelet adhesion and activation. *Arterioscler Thromb Vasc Biol.* (2010) 30:2341–9.
12. Wu L, Zhao F, Dai M, Li H, Chen C, Nie J, et al. P2y12 receptor promotes pressure overload-induced cardiac remodeling via platelet-driven inflammation in mice. *Hypertension.* (2017) 70:759–69. doi: 10.1161/HYPERTENSIONAHA.117.09262
13. Khodadi E. Platelet function in cardiovascular disease: activation of molecules and activation by molecules. *Cardiovasc Toxicol.* (2020) 20:1–10. doi: 10.1007/s12012-019-09555-4
14. Dib P, Quirino-Teixeira A, Merij L, Pinheiro M, Rozini S, Andrade F, et al. Innate immune receptors in platelets and platelet-leukocyte interactions. *J LeukocYTE Biol.* (2020) 108:1157–82. doi: 10.1002/JLB.4MR0620-701R
15. Gleissner C. Platelet-derived chemokines in atherogenesis: what’s new? *Curr Vasc Pharmacol.* (2012) 10:563–9. doi: 10.2174/157016112800784521
16. Smeda M, Przyborowski K, Stojak M, Chlopicki S. The endothelial barrier and cancer metastasis: does the protective facet of platelet function
Leng et al. Functions of Platelet-Derived MicroRNAs

80. Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets. (2001) 12:261–73. doi: 10.1080/09537100120068176

81. Ponomareva AA, Nevzorova TA, Mordakhanova ER, Andrianova IA, Rauova L, Litvinov RI, et al. Intracellular origin and ultrastructure of platelet-derived microparticles. J Thromb Haemost. (2017) 15:1655–67. doi: 10.1111/jth.13745

82. Holinstat M. Normal platelet function. Cancer Metastasis Rev. (2017) 36:195–8.

83. Söllner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S, Tempst P, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature. (1993) 362:318–24. doi: 10.1038/362318a0

84. Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med. (2013) 19:1609–16. doi: 10.1038/nm.3385

85. Söllner T, Whiteheart SW, Brunner M, Erdjument-Bromage H, Geromanos S, Tempst P, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature. (1993) 362:318–24. doi: 10.1038/362318a0

86. Laffont B, Corduan A, Ple H, Duchez AC, Cloutier N, Boirard E, et al. Activated platelets can deliver miRNA regulatory Ago2miRNA complexes to endothelial cells via microparticles. Blood. (2013) 122:253–61. doi: 10.1182/blood-2013-03-492801

87. Diehl P, Fricke A, Sander L, Stamm J, Basler N, Hutm N, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. (2012) 93:63–44. doi: 10.1093/cvr/cvs007

88. Chevillet JR, Kang Q, Ruf JK, Briggs HA, Voytech LN, Hughes SM, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A. (2014) 111:14888–93.

89. Provost P. The clinical significance of platelet microparticle-associated microRNAs. Clin Lab Med. (2017) 37:556–67. doi: 10.1016/cilm-2016-0895

90. Berckmans RJ, Nieuwland R, Böing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombogenesis. Thromb Haemost. (2001) 85:639–46.

91. Takeuchi K, Satoh M, Kuno H, Yoshida T, Kondo H, Takeuchi M. Platelet-like particle formation in the human megakaryoblastic leukaemia cell lines, MEG-01 and MEG-01s. Br J Haematol. (1998) 100:436–44. doi: 10.1046/j.1365-2451.1998.00576.x

92. Pan Y, Liang H, Liu H, Li D, Chen X, Li L, et al. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. J Immunol. (2014) 192:437–46. doi: 10.4049/jimmunol.1301790

93. Li T, Tan M, Xiang Q, Zhou Z, Yan H. Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. Thromb Res. (2017) 154:96–105. doi: 10.1016/j.thromres.2017.04.016

94. Zhang Y, Zhang W, Cai L, Liu T. Platelets activated by the anti-j2GPI/j2GPI complex release microRNAs to inhibit migration and tube formation of human umbilical vein endothelial cells. Cell Mol Biol Lett. (2017) 23:23–4. doi: 10.1165/cibl.2017.00013

95. Anene C, Graham AM, Boyne J, Roberts W. Platelet microparticle delivered microRNA-Let-7a promotes the angiogenic switch. Biochim Biophys Acta Mol Basis Dis. (2018) 1864:2533–43. doi: 10.1016/j.bbadis.2018.04.013

96. Bao H, Chen XY, Huang K, Zhuang F, Bao M, Han Y, et al. Platelet-derived microparticles promote endothelial cell proliferation in hypertension via miR-142-3p. FASEB J. (2018) 32:3912–23. doi: 10.1096/fj.201710737R

97. Tan M, Yan HB, Li JN, Li WK, Fu YY, Chen W, et al. Thrombin stimulated platelet-derived exosomes inhibit platelet-derived growth factor receptor-beta expression in vascular smooth muscle cells. Cell Mol Biol (Let). (2018) 24:3. doi: 10.1165/cibl.2018.00913

98. Sadallah S, Schmied L, Eken C, Charoudeh HN, Amicarella F, Schifferli JA. Platelet-derived exosomes reduce NK cell function. J Immunol. (2016) 197:1663–71. doi: 10.4049/jimmunol.1502658
Platelet-derived exosomal microRNAs as biomarkers for prediction of thrombotic risk in patients with acute myocardial infarction and primary angioplasty. J Pers Med. (2021) 11:508. doi: 10.3390/jpm11060508

20. Qiu H, Zhang Y, Zhao Q, Jiang H, Yan J, Liu Y. Platelet miR-587 may be used as a potential biomarker for diagnosis of patients with acute coronary syndrome. Clin Lab. (2020) 66:66. doi: 10.7754/ClinLab.2019.190703

21. Zhang DM, Deng J, Wu YG, Tang T, Xiong L, Zheng Y, et al. MicroRNA-223-2p protect against radiation-induced cardiac toxicity by alleviating myocardial oxidative stress and programmed cell death via targeting the AMPK pathway. Front Cell Dev Biol. (2021) 9:801661. doi: 10.3389/fceli.2021.801661

22. Liu X, Xu Y, Deng Y, Li H. MicroRNA-223 regulates cardiac fibrosis after myocardial infarction by targeting RASAl. Cell Physiol Biochem. (2018) 46:1439–54. doi: 10.15861/00489818

23. Liu X, Deng Y, Xu Y, Jin W, Li H. MicroRNA-223 protects neonatal rat cardiomyocytes and H9c2 cells from hypoxia-induced apoptosis and excessive autophagy via the Akt/mTOR pathway by targeting PARP-1. J Mol Cell Cardiol. (2018) 113:133–46. doi: 10.1016/j.yjmcc.2018.03.018

24. Duan S, Wang C, Xu X, Zhang X, Su G, Li Y, et al. Peripheral serum exosomes isolated from patients with acute myocardial infarction promote endothelial cell angiogenesis via the miR-126-3p/TSC1/mTORC1/HIF-1α pathway. Int J Nanomed. (2022) 17:1577–92. doi: 10.2147/IJN.S338937

25. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. (2005) 365:217–23. doi: 10.1016/S0140-6736(05)17741-1

26. Markotou M, Kontaraki J, Papadakis J, Kochiadakis G, Vrentzos G, Maragkoudakis S, et al. Platelet microRNAs in hypertensive patients with and without cardiovascular disease. J Hum Hypertens. (2019) 33:149–56. doi: 10.1038/s41437-018-0123-5

27. Huang YQ, Huang C, Chen YJ, Li J, Feng YQ. Plasma expression level of miRNA-let-7 is positively correlated with carotid intima-media thickness in patients with essential hypertension. J Hum Hypertens. (2017) 31:843–7. doi: 10.1038/jhh.2017.52

28. Parthenakis F, Markotou M, Kontaraki J, Patraniakos A, Nakou H, Touloupaki M, et al. Low levels of MicroRNA-21a are a marker of reduced arterial stiffness in well-controlled hypertension. J Clin Hypertens. (2017) 19:235–40. doi: 10.1111/jch.12900

29. Fernandes T, Magalhães FC, Roque FR, Phillips MI, Oliveira EM. Exercise training prevents the microvascular rarefaction in hypertension balancing angiogenic and apoptotic factors: role of microRNAs-16, −21, and −126. Hypertension. (2012) 59:513–20. doi: 10.1161/HYPERTENSIONAHA.111.185801

30. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. (1993) 16:434–44. doi: 10.2337/diacare.16.2.434

31. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, et al. The evolving diabetes burden in the United States. Ann Intern Med. (2004) 140:945–50. doi: 10.7326/0003-4819-140-11-200406010-00035

32. Nakagami H, Kanaeda Y, Ogihara T, Morishita R. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev. (2005) 1:59–63. doi: 10.2174/15739099052952530

33. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. (2004) 27:1798–811. doi: 10.2337/diacare.27.7.1798

34. Russo I, Penna C, Musso T, Popara J, Allootti G, Cavalot F, et al. Platelets, diabetes and myocardial ischaemia/reperfusion injury. Cardiovasc Diabetol. (2017) 16:117. doi: 10.1186/s12933-017-0550-6

35. Nomura S, Miyazaki Y, Miyake T, Suzuki M, Kawakatsu T, Kido H, et al. Platelet-derived exosomal microRNAs-21, 22, and 23-3p inhibit the proliferation and functional activity of human umbilical vein endothelial cells. Platelets. (2018) 29:582–9. doi: 10.1080/08081860.2017.1381885

36. Liu X, Sun Y, Sun Q, Jing B, Liu S, Liu X, et al. Platelet-derived exosomal microRNA-25-3p inhibits coronary vascular endothelial cell inflammation through adaman1 via the NFκB signaling pathway in ApoE−/− mice. Front Immunol. (2019) 10:2205. doi: 10.3389/fimmu.2019.02205

37. Hromadka M, Motovska Z, Hlinomaz O, Kala P, Tousek F, Jarkovsky J, et al. MiR-126-3p and MiR-223-3p as biomarkers for prediction of thrombotic risk in patients with acute myocardial infarction and primary angioplasty. J Pers Med. (2021) 11:508. doi: 10.3390/jpm11060508

38. Liu X, Zhang Y, Zhao Q, Jiang H, Yan J, Liu Y. Platelet miR-587 may be used as a potential biomarker for diagnosis of patients with acute coronary syndrome. Clin Lab. (2020) 66:66. doi: 10.7754/ClinLab.2019.190703

39. Zhang DM, Deng J, Wu YG, Tang T, Xiong L, Zheng Y, et al. MicroRNA-223-2p protect against radiation-induced cardiac toxicity by alleviating myocardial oxidative stress and programmed cell death via targeting the AMPK pathway. Front Cell Dev Biol. (2021) 9:801661. doi: 10.3389/fceli.2021.801661

40. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diabetics Vasc Dis Res. (2008) 5:138–44. doi: 10.3132/dvd.2008.0203
143. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. *J Thromb Haemost.* (2004) 2:1282–91.

144. Fejes Z, Pólisha S, Czimermer Z, Káplár M, Penyige A, Gál Szabó G, et al. Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus. *Thromb Haemost.* (2017) 117:529–42. doi: 10.1160/TH16-01-0226.

145. Zampetaki A, Mayr M. Sweet dicer: impairment of micro-RNA processing in inflammation and cardiovascular diseases. *Expert Rev Hematol.* (2021) 14:537–46. doi: 10.1080/17474868.2021.1943353

146. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med.* (2003) 348:891–9.

147. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *Lancet.* (2010) 376:1741–50. doi: 10.1016/S0140-6736(10)61543-7.

148. Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Paolo KE, et al. Cardio-ondcology drug interactions: a scientific statement from the American heart association. *Circulation.* (2012) 125:e81–38. doi: 10.1161/CIR.0b013e3182400156.

149. Plantureux L, Mède C, Crescience L, Carminita E, Robert S, Cointe S, et al. The interaction of platelets with colorectal cancer cells inhibits tumor growth but promotes metastasis. *Cancer Res.* (2020) 80:291–303. doi: 10.1158/0008-5472.CAN-19-1181.

150. Prattichizzo F, Giuliani A, De Nigris V, Pujadas G, Ceka A, La Sala L, et al. Protective effect of let-7 miRNA family in regulating inflammation and cardiovascular diseases. *Expert Rev Hematol.* (2011) 4:365–75. doi: 10.1586/erh.11.37.

151. Xue WL, Chen RQ, Zhang QQ, Li XH, Cao L, Li MY, et al. Hydrogen sulfide rescues high glucose-induced migration dysfunction in HUVECs by upregulating miR-126-3p. *Am J Physiol Cell Physiol.* (2020) 318:C857–69. doi: 10.1152/ajpcell.00406.2019.

152. Akbarinia A, Kargarfard M, Naderi M. Effects of endurance training on platelet-derived microRNAs in patients with diabetes mellitus with or without ischemic stroke. *J Diabetes Complications.* (2014) 28:705–10. doi: 10.1016/j.jdiacomp.2014.04.012.

153. Luo M, Li R, Deng X, Ren M, Chen N, Zeng M, et al. Platelet-derived miR-103b as a novel biomarker for the early diagnosis of type 2 diabetes. *Acta Diabetol.* (2015) 52:943–9. doi: 10.1007/s00592-015-0733-0.

154. Liao, Li R, Ren M, Chen N, Deng X, Tan X, et al. Hyperglycaemia-induced reciprocal changes in miR-30c and PAI-1 expression in platelets. *Sci Rep.* (2016) 6:36687. doi: 10.1038/srep36687.

155. Pratichizzo F, Giuliani A, De Nigris V, Pujadas G, Ceka A, La Sala L, et al. Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity? *Diabetes Obes Metab.* (2016) 18:835–47. doi: 10.1111/dom.12688.

156. Xu WL, Chen QQ, Zhang LL, Cui KC, Zeng YR, et al. Hydrogen sulfide rescues high glucose-induced migration dysfunction in HUVECs by upregulating miR-126-3p. *Am J Physiol Cell Physiol.* (2020) 318:C857–69. doi: 10.1152/ajpcell.00406.2019.

157. Cavarretta E, Chiariello GA, Condorelli G. Platelets, endothium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. *Europ Heart J.* (2013) 34:3400–2. doi: 10.1093/eurheartj/eht732.

158. Li K, Li R, Ren M, Chen N, Deng X, Tan X, et al. Hyperglycemia-induced modified miR-21-3p and miR-19b-3p in platelets. *Sci Rep.* (2016) 6:36687. doi: 10.1038/srep36687.

159. Pratichizzo F, Giuliani A, De Nigris V, Pujadas G, Ceka A, La Sala L, et al. Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity? *Diabetes Obes Metab.* (2016) 18:835–47. doi: 10.1111/dom.12688.

160. Xue WL, Chen QQ, Zhang LL, Cui KC, Zeng YR, et al. Hydrogen sulfide rescues high glucose-induced migration dysfunction in HUVECs by upregulating miR-126-3p. *Am J Physiol Cell Physiol.* (2020) 318:C857–69. doi: 10.1152/ajpcell.00406.2019.

161. Cavarretta E, Chiariello GA, Condorelli G. Platelets, endothium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. *Europ Heart J.* (2013) 34:3400–2. doi: 10.1093/eurheartj/eht732.

162. Akbarinia A, Kargarfard M, Naderi M. Aerobic training improves platelet function in type 2 diabetic patients: role of microRNA-130a and GPIIb. *Acta Diabetol.* (2018) 55:893–9. doi: 10.1007/s00592-018-1167-2.

163. Taghizadeh M, Kargarfard M, Braune S, Jung F, Naderi M. Long-term aerobic exercise training in type 2 diabetic patients alters the expression of miRNA-223 and its corresponding target, the P2RY12 receptor, attenuating platelet activation. *Clin Hemorheol Microcirc.* (2021) 80:107–16. doi: 10.3237/dh.2021-CIR.0000000000001056.

164. Taghizadeh M, Ahmadizad S, Naderi M. Effects of endurance training on platelet-derived microRNAs in patients with diabetes mellitus. *Clin Hemorheol Microcirc.* (2021) 80:107–16. doi: 10.3237/dh.2021-CIR.0000000000001056.

165. De Boer HC, van Solingen C, Prins J, Duijs JM, Huisman MV, Rabelink TH, et al. Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus. *Thromb Haemost.* (2017) 117:529–42. doi: 10.1160/TH16-01-0226.

166. Sabatino J, De Rosa S, Polimeni A, Sorrentino S, Indolfi C. Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis. *JACC Cardiooncol.* 34:3451–7. doi: 10.1016/j.jchoc.2017.09.007.

167. Camilli M, Iannaccone G, La Vecchia G, Cappinnoli L, Scciavillani R, Minotti G, et al. Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases. *Expert Rev Hematol.* (2021) 14:537–46. doi: 10.1080/17474868.2021.1943353.
182. He Q, Ye A, Ye W, Liao X, Qin G, Xu Y, et al. Cancer-secreted exosomal miR-21-3p induces angiogenesis and vascular permeability by targeting KRIT1. *Cell Death Dis.* (2021) 12:576, doi: 10.1038/s41419-021-03803-8

183. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. *PLOS ONE.* (2011) 6:e19139, doi: 10.1371/journal.pone.0019139

184. Shi L, Fisslthaler B, Zippel N, Frömel T, Hu I, Lkhagvaznaa A, et al. MiCroRNA-223 antagonizes angiogenesis by targeting fibronectin and preventing growth factor signaling in endothelial cells. *Circ. Res.* (2013) 113:1320–30, doi: 10.1161/CIRCRESAHA.113.301824

185. Bozec A, Zangari J, Butoiri-Pepino M, Ille M, Lalvee S, Juhel T, et al. MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma. *Oncotarget.* (2017) 8:57174–86, doi: 10.18632/oncotarget.19170

186. Yu Q, Xiang L, Yin L, Liu X, Yang D, Zhou J. Loss-of-function of miR-142 by hypermethylation promotes TGF-β mediated tumour growth and metastasis in hepatocellular carcinoma. *Cell Prolif.* (2017) 50:e12384, doi: 10.1111/cpr.12384

187. Gu Y, Pais G, Becker V, Körbel C, Ampofo E, Ebert E, et al. Suppression of endothelial miR-22 mediates non-small cell lung cancer cell-induced angiogenesis. *Mol Ther Nucleic Acids.* (2021) 26:849–64, doi: 10.1016/j.omtn.2021.10.003

188. Wisman PP, Roest M, Asselbergs FW, de Groot PG, Moll FL, van der Kołton-Wróź M, et al. Association of plasma miR-223 and platelet reactivity with cardiovascular risk and thrombotic markers and microRNA levels. *Diabetes Mellitus: a Double-Blind Randomised Controlled Trial of the Effects on Cardiovasc Diabetol.* (2011) 6:e19139. doi: 10.1371/journal.pone.0019139

189. Farré AJ, Tamargo J, Mateos-Cáceres PJ, Azcona L, Macaya C. Old and new determinants of the antiplatelet response in clopidogrel-treated patients with acute coronary syndrome patients with high platelet reactivity after dual antiplatelet therapy. *Cardiovasc Drugs Ther.* (2019) 33:129–37, doi: 10.1007/s10557-019-06885-x

190. Stuckey TD, Kirtane AJ, Brodie BR, Witzenbichler B, Litherland C, Weisz, et al. Predicting resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction. *J Int Med Res.* (2019) 49:3000605211016209, doi: 10.1177/00222515191016209

191. Kok MG, Mandolini C, Moerland PD, de Ronde MW, Sondermeer BJ, Halliani A, et al. Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity. *Int J Cardiol.* (2016) 203:262–3, doi: 10.1016/j.ijcard.2015.10.098

192. Chen YC, Lin FY, Lin YW, Cheng SM, Chang CC, Lin RH, et al. Platelet MicroRNA-365-3p expression correlates with high on-treatment platelet reactivity in coronary artery disease patients. *Cardiovasc Drugs Ther.* (2019) 33:129–37, doi: 10.1007/s10557-019-06885-3

193. Ding T, Zeng X, Cheng B, Ma X, Yuan H, Nie X, et al. Platelets in acute coronary syndrome patients with high platelet reactivity after dual antiplatelet therapy exhibit upregulation of miR-204-5p. *Ann Clin Lab Sci.* (2019) 49:619–31.

194. Lin S, Xu X, Hu H, Cheng J, Chen R, Hu Y, et al. The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance. *Pharmac Res Perspect.* (2019) 7:e00751. doi: 10.1002/prp2.751

195. Rytkin E, Mirzaev K, Bure I, Akmalova K, Abdullahs A, Kachanova A, et al. MiRNAs as novel biomarkers for P2Y12 – inhibitors resistance prediction. *Pharmaceutics Pers Med.* (2021) 17:14575–82, doi: 10.2147/PGMP.S334612

196. Liu WW, Wang H, Chen XF, Hu SW, Liu ML. miR-34b-5p may promote antiplatelet efficiency of aspirin by inhibiting thromboxane synthase expression. *Thromb Haemost.* (2019) 119:1451–60, doi: 10.1055/s-0039-1692681

197. Zhang Q, Zhu F, Luo Y, Liao J, Cao J, Xue T. Platelet miR-107 participates in clopidogrel resistance after PCI treatment by regulating P2Y12. *Acta Haematol.* (2022) 145:46–53, doi: 10.1002/aja.215781

198. Shi R, Zhou X, Ji WJ, Zhang YY, Ma YQ, Zhang JQ, et al. The emerging role of miR-223 in platelet reactivity: implications in antiplatelet therapy. *Biomed Res Int.* (2015) 2015:981841, doi: 10.1155/2015/981841

199. Wang J, Yao Y, Zhang J, Tang X, Meng X, Wang M, et al. Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis. *Ann Transl Med.* (2020) 8:364, doi: 10.21037/atm.2020.02.88

200. Yeung J, Li W, Holinast M. Platelet signaling and disease: targeted therapy for thrombosis and other related diseases. *Pharmacol Rev.* (2018) 70:526–48, doi: 10.1124/pr.117.014530

201. Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. *Clin Sci (Lond).* (2010) 119:87–95, doi: 10.1042/CS20090645

202. Grabmaier U, Clauss S, Gross L, Klier I, Franz WM, Steineck G, et al. Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction - The STAIRAGMIMIR analysis. *Int J Cardiol.* (2017) 244:30–36, doi: 10.1016/j.ijcard.2017.06.054

203. Pedersen OB, Grove EL, Kristensen SD, Nissen PH, Hvas AM. MicroRNA as biomarkers for platelet function and maturity in patients with cardiovascular disease. *Thromb Haemost.* (2021) 122:181–95, doi: 10.1055/a-0041-1730735

204. Li S, Guo LZ, Kim MH, Han JY, Serebruany V. Platelet microRNA for predicting acute myocardial infarction. *J Thromb Thrombolysis.* (2014) 37:455–64, doi: 10.1007/s11239-017-1537-6

205. Fordzik J, Eyeletten-Postula C, Jakubik D, Czajka P, Nowak A, De Rosa S, et al. MiR-126 is an independent predictor of long-term all-cause mortality in patients with type 2 diabetes mellitus. *J Clin Med.* (2021) 10:2371. doi: 10.3390/jcm10112371

206. Rossetti GB, Galdoni M, Pengo V, Vescovini R, Mazzoni P, Tassoni MI, et al. MiRNA-126 as a new predictor biomarker in venous thromboembolism of persistent residual vein obstruction: a review of the literature plus a pilot study. *Semin Thromb Hemost.* (2021) 47:982–91, doi: 10.1055/s-0041-1726341

207. Schulte C, Molz S, Appelbaum S, Karakas M, Ojeda F, Lau DM, et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients...
with symptomatic coronary artery disease. PLoS One. (2015) 10:e0145930. doi: 10.1371/journal.pone.0145930

219. Szelenberger R, Karbowiak MS, Kacprzak M, Maciak K, Bijak M, Zielinska M, et al. Screening analysis of platelet miRNA profile revealed miR-142-3p as a potential biomarker in modeling the risk of acute coronary syndrome. Cells. (2021) 10:3526. doi: 10.3390/cells10123526

220. Bijak M, Dzieciol M, Rywaniak J, Saluk J, Zielinska M. Platelets miRNA as a prediction marker of thrombotic episodes. Dis Markers. (2016) 2016:2872507. doi: 10.1155/2016/2872507

221. Yang S, Zhao J, Chen Y, Lei M. Biomarkers associated with ischemic stroke in diabetes mellitus patients. Cardiovasc Toxicol. (2016) 16:213–22. doi: 10.1007/s12012-015-9329-8

222. In ‘t Veld S, Wurdinger T. Tumor-educated platelets. Blood. (2020) doi: 10.1182/blood.2020011187

223. Vaidyanathan R, Soon RH, Zhang P, Jiang K, Lim CT. Cancer diagnosis: from tumor to liquid biopsy and beyond. Lab Chip. (2018) 19:11–34.

224. Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res. (2018) 78:3407–12. doi: 10.1158/0008-5472.CAN-18-0887

225. Miao S, Zhang Q, Chang W, Wang J. New insights into platelet-enriched miRNAs: production, functions, roles in tumors, and potential targets for tumor diagnosis and treatment. Mol Med. (2021) 20:1539–66. doi: 10.1186/s12992-020-00280-z

226. Wang H, Wei X, Wu B, Su J, Tan W, Yang K. Tumor-educated platelet miR-34c-3p and miR-18a-5p as potential liquid biopsy biomarkers for nasopharyngeal carcinoma diagnosis. Cancer Manage. (2019) 11:3351–60. doi: 10.2147/CMAR.S195655

227. Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell. (2015) 28:666–76. doi: 10.1016/j.ccell.2015.09.018

228. Zhong S, Golpon H, Zardo P, Borlak J. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl. Res. (2021) 236:164–96. doi: 10.1016/j.trsl.2020.11.012

229. Omland T. Cardio-protective therapy in cardio-oncology: quo vadis? Circulation. (2014) 126(25):414–30. doi: 10.1161/CIRCULATIONAHA.114.011554

230. Delgado Lagos F, Elghezzawy A, Kyselova A, Meyer Zu Heringdorf D, Ratiu A, et al. MicroRNA-223 is a potential biomarker in modeling the risk of acute coronary syndrome. Cells. (2016) 5:2872507. doi: 10.1155/2016/2872507

231. Zhou Y, Abraham S, Andre P, Edelstein LC, Shaw CA, Dangelmaier CA, et al. Suppression of miR-140-5p in platelets ameliorates hyperglycemia inhibition of endothelial miR-140-3p mediates angiogenic dysfunction in diabetes mellitus. J Diabetes Complications. (2019) 33:374–82. doi: 10.1016/j.diabcomp.2019.02.001

232. Jordan SD, Krüger M, Willmes DM, Redemann N, Wunderlich FT, Brönneke HS, et al. Obesity-induced overexpression of microRNA-143 inhibits insulin-stimulated Akt activation and impairs glucose metabolism. Nat Cell Biol. (2011) 13:434–46. doi: 10.1038/ncb2111

233. Wyss CB, Duffy N, Peyvandi S, Barras D, Martinez Ustarro A, Coquoz O, et al. Gain of HIF1 Activity and Loss of miRNA let-7d promote breast cancer metastasis to the brain via the PDGF/PDGFR Axes. Cancer Res. (2021) 81:594–605. doi: 10.1158/0008-5472.CAN-19-3560

234. Ward JA, Esa N, Pidkitti R, Freedman JE, Keaney JF, Tamrideri K, et al. Circulating cell and plasma microRNA profiles differ between non-ST-Segment and ST-segment elevation myocardial infarction. Fam Med Med Sci Res. (2013) 1:2108. doi: 10.1016/j.fmmsr.2012.10.008

235. Goren Y, Meiri E, Hogan C, Mitchell H, Lebanon Y, Salaman N, et al. Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am J Cardiol. (2014) 113:976–81. doi: 10.1016/j.amjcard.2013.11.060

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Leng, Ding, Dai, Liu, Fang, Wang, Wu and Wang. This is an open-access article published under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.